Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to tailor ovarian cancer treatment for women over 70

NCT ID NCT06572735

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 50 women aged 70 and older with advanced ovarian cancer who are starting PARP inhibitors for the first time. Researchers will track how much of the planned dose patients actually receive, and look at factors like age, genetics, and overall health that might affect tolerance. The goal is to better understand how to manage side effects and keep patients on effective treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PARP inhibitors
What this could lead to
If successful, this could help doctors better manage side effects and dosing of PARP inhibitors in elderly patients, potentially improving treatment outcomes.
What could go wrong
This is a small observational study (50 patients) that does not test a new treatment. It only gathers data, so it will not directly change care immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients of 70 years and elder with an advanced ovarian cancer who are scheduled to start a maintenance therapy with PARP inhibitors for the first time. The necessary number of patients in the study is 50.

Ages

70 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 70 years * Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO stage III or IV) * PARP inhibitors -naive patient who need to initiate maintenance treatment with PARP inhibitors for the first time (according the the marketing authorization) * Patient with a life expectancy of more then 3 months * Informed patient which does not oppose to participate to the study Exclusion Criteria: * Prior treatment with PARP inhibitors * Patient incapable to take oral tablets/capsules * Participation in a drug trial that does not authorize concurrent participation in another trials * Person unable to attend scheduled examinations/appointments as part of routine care for geographical, social or psychological reasons * Concomitant cancer or f cancer history (other than those included in the inclusion criteria) treated and considered cured for less than 2 years. However, patients with the following pathologies are eligible: * Basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma * Stage 1B or less cervical carcinoma * Non-invasive superficial bladder cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Georges François Leclerc

    RECRUITING

    Dijon, 21079, France

  • Centre Hospitalier Privé Saint-Grégoire - Les Hôpitaux Privés Rennais

    RECRUITING

    Saint-Grégoire, 35760, France

  • Centre Hospitalier Universitaire d'Amiens Picardie Site Sud

    RECRUITING

    Amiens, 80054, France

  • Centre Hospitalier Valence

    RECRUITING

    Valence, 26953, France

  • Centre de lutte contre le cancer Jean Perrin

    RECRUITING

    Clermont-Ferrand, 63011, France

  • Clinique Mathilde

    RECRUITING

    Rouen, 76100, France

  • Clinique de l'Europe

    RECRUITING

    Amiens, 80090, France

  • Groupe Hospitalier Diaconesses Croix Saint Simon

    RECRUITING

    Paris, 75020, France

  • Groupe Hospitalier Public Sud de l'Oise

    RECRUITING

    Creil, 60100, France

  • Hôpital Femme-Mère-Enfant

    RECRUITING

    Bron, 69500, France

  • Hôpital Privé Jean Mermoz

    RECRUITING

    Lyon, 69008, France

  • Institut de Cancérologie et d'Hématologie Universitaire de Saint Etienne

    RECRUITING

    Saint-Priest-en-Jarez, 42271, France

  • Médipôle Hôpital Mutualiste

    RECRUITING

    Villeurbanne, 69100, France

  • Service Hôpital de jour / Oncologie Médicale, Hôpital de la Croix Rousse

    RECRUITING

    Lyon, 69004, France

  • Service Oncologie Médicale, Hôpital Lyon Sud

    RECRUITING

    Pierre-Bénite, 69495, France

  • Service de Gériatrie, Hôpital Dr Frédéric Dugoujon

    RECRUITING

    Lyon, 69317, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.